
	Three months ended				Six months ended
Product	June 30,		June 30,		June 30,		June 30,
	2011		2010		2011		2010
Par Pharmaceutical
Metoprolol succinate ER (Toprol-XL®)	$	63,706	$	119,596	$	127,124	$	302,887
Budesonide (Entocort® EC)		16,357		-		16,357		-
Sumatriptan succinate injection (Imitrex®)		15,284		17,463		31,983		34,747
Propafenone (Rythmol SR®)		13,311		-		35,350		-
Amlodipine and Benazepril HCI (Lotrel®)		12,505		-		30,675		-
Dronabinol (Marinol®)		8,118		7,183		14,989		11,274
Chlorpheniramine/Hydrocodone (Tussionex®)		7,022		-		19,701		-
Tramadol ER (Ultracet ER®)		5,873		5,676		11,954		10,962
Meclizine Hydrochloride (Antivert®)		4,562		9,398		9,437		19,552
Cholestyramine Powder (Questran®)		4,077		2,974		7,760		6,910
Nateglinide		3,815		3,470		8,120		4,988
Cabergoline (Dostinex®)		2,920		2,520		5,873		6,514
Methimazole (Tapazole®)		2,456		2,590		4,560		5,430
Clonidine TDS (Catapres TTS®)		-		26,290		4,793		44,751
Other (1)		33,398		31,679		66,583		51,709
Other product related revenues (2)		9,045		3,099		16,934		4,253
Total Par Pharmaceutical Revenues	$	202,449	$	231,938	$	412,193	$	503,977

Strativa
Megace® ES	$	14,050	$	15,493	$	28,135	$	29,291
Nascobal® Nasal Spray		6,274		4,407		10,152		8,002
OravigTM		1,027		-		1,776		-
Zuplenz®		263		-		485		-
Other product related revenues (2)		125		3,636		4,399		6,136
Total Strativa Revenues	$	21,739	$	23,536	$	44,947	$	43,429

(1)

The further detailing of revenues of the other approximately 60 generic drugs is impracticable due to the low volume of revenues associated with each of these generic products. No single product in the other category is in excess of 3% of total generic revenues for six-month periods ended June 30, 2011 or June 30, 2010.

(2)

Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as diazepam rectal gel, the generic version of Diastat®, and fenofibrate, the generic version of Tricor®. Other product related revenues included in the Strativa segment related to a co-promotion arrangement with Solvay for Androgel® in 2010. This co-promotion arrangement with Solvay was terminated in December 2010 for an associated $2 million payment. During the six-month period ended June 30, 2011, Strativa earned $4.3 million of royalty income from its share of the proceeds from Optimer Pharmaceuticals' sale of certain rights in fidaxomicin to a third party. Under the terms of the 2007 termination agreement, we are also entitled to royalty payments on future sales of fidaxomicin.